MediciNova, Inc.
MNOV Healthcare Biotechnology
MediciNova, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $409,700.00, down 59.0% from fiscal 2023. In the quarter to June 2026, revenue grew 240.6%, EPS grew 28.6% and free cash flow grew 16.8%, each against the same quarter a year earlier.
Follow MNOV
MediciNova, Inc. (MNOV) Altman Z-score
MediciNova, Inc.'s Altman Z-score for fiscal 2025 is −4.10, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | −4.10 | (7.05) |
| FY2023 | 2.95 | (12.32) |
| FY2021 | 15.27 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.60 | — | 0.72 | |
| Retained earnings / total assets | (9.62) | — | −13.47 | |
| EBIT / total assets | (0.29) | — | −0.96 | |
| Market value of equity / total liabilities | 16.00 | — | 9.60 | |
| Sales / total assets | 0.01 | — | 0.01 | |
| Altman Z-score | Distress zone | −4.10 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −18.54 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| NTRB Nutriband Inc. compare | 27.2× |
| MNOV MediciNova, Inc. | −4.1× |
| CRDF Cardiff Oncology, Inc. compare | −4.7× |
| HRTX Heron Therapeutics, Inc. compare | −8.8× |
| ACRV Acrivon Therapeutics, Inc. compare | — |
| OKYO OKYO Pharma Limited Sponsored ADR compare | — |
| MAIA MAIA Biotechnology, Inc. compare | — |
| PDSB PDS Biotechnology Corporation compare | — |
| CGTX Cognition Therapeutics, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets